drugset / Trial / NCT01081652

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)

NCT01081652

Phase 3 Completed 238 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupOpen-labelTreatment

Summary

This was an open-label, randomized, comparative, phase III study to evaluate the safety and efficacy of Crinone 8% in comparison with progesterone 60 mg intramuscular (i.m.) administered once a day in luteal phase support in 200 Chinese female subjects undergoing IVF/ET.

Timeline

Start
2004-05
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Progesterone Other / unclassified 8 % Intravenous
Comparator Progesterone Other / unclassified 60 mg Intravenous

Indications